Baxter International, Inc. Receives Approval For PREFLUCEL Seasonal Influenza Vaccine in Austria
VIENNA, Austria--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter’s proprietary advanced Vero cell technology.